retatrutide fda approval status safety trial results Mazdutide vs retatrutide: dual agonist meets triple agonist in the next-gen weight loss showdown Retatrutide 2026: – FDA approves Retatrutide this year?

Lam RW, Kennedy SH, Adams C, Bahji A, Beaulieu S, Bhat V, et al

Phase 2 trial data (NEJM 2023) showed approximately 17.5% mean body weight reduction at 24 weeks at the highest dose, but week-4 figures were not reported as a primary endpoint

More fat burned = glycogen spared = longer time to fatigue Especially beneficial for CrossFit, endurance athletes, and metabolic conditioning MOTS-c improves physical performance by regulating mitochondrial respiration and metabolic substrate use. Reynolds et al., Nature Communications Supports Anti-Aging and Stress Resistance Emerging research suggests that MOTSc acts like a mitochondrial stress hormone , improving longevity pathways similar to caloric restriction

Your doctor will also help you track progress with specific milestones or identify warning signs

The connection between weight loss methods and hair outcomes GLP-1 medications are not the only weight loss approach that can trigger hair shedding

Zohra SF, Meriem B, Samira S, et al